Name | MYRISTOLEIC ACID |
Synonyms | MYRISTOLEIC ACID 9-tetradecenoic acid CIS-9-TETRADECENOIC ACID 9-Tetradecenoic acid, (9Z)- DELTA 9 CIS TETRADECENOIC ACID |
CAS | 544-64-9 |
EINECS | 208-876-8 |
Molecular Formula | C14H26O2 |
Molar Mass | 226.36 |
Density | 0.9 g/mL at 25 °C(lit.) |
Melting Point | −4.5-−4 °C(lit.) |
Boling Point | 144 °C0.6 mm Hg(lit.) |
Flash Point | 62 °C |
Appearance | Morphological Liquid |
pKa | 4.78±0.10(Predicted) |
Storage Condition | -20°C |
Refractive Index | n20/D 1.4562(lit.) |
Physical and Chemical Properties | EPA Chemical Information 9-Tetradecenoic acid, (9Z)- (544-64-9) |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
UN IDs | NA 1993 / PGIII |
WGK Germany | 3 |
Downstream Products | cetyl myristoleate |
biological activity
Myristoleic acid is a cytotoxic component in Serenoa repens extract, which can induce apoptosis and necrosis of human prostate cells.
in vitro study
Myristoleic acid induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells.
Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation.
Cell Proliferation Assay
Cell Line: Human prostatic carcinoma LNCaP cells.
Concentration: 0, 50, 100, 150, 200, 250 μg/mL.
Incubation Time: 24 h.
Result: When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively.
in vivo studies
Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice.
Animal Model: C57BL/6 mice at 5 weeks.
Dosage: 0.2, 2 mg/kg
Administration: IP every 24 h for 4 days.
Result: Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/ B. Pm and ES/BS in a dose-dependent manner.